Skip to Main Content

NGM Biopharmaceuticals wants to be the next billion-dollar biotech on Wall Street, and so it’s moving forward with an IPO that offers a springtime referendum on investor sentiment.

Back in September, South San Francisco-based NGM filed paperwork to go public but fell silent as biotech indices tumbled in the fourth quarter. Now, apparently pleased with the state of the market, NGM has revived those plans and is pitching an offering that would value the company at about $1.1 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!